Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Azim, Hatem A ^a   Singhal, Sandeep ^a   Ignatiadis, Michail ^a   Desmedt, Christine ^a   Fumagalli, Debora ^a   Veys, Isabelle ^a   Larsimont, Denis ^a   Piccart, Martine ^a   Michiels, Stefan ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; OSTEONECTIN; PROTEIN SPARC7; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SIZE; CELL PROLIFERATION; COHORT ANALYSIS; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; EARLY CANCER; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; PATIENT SELECTION; PHARMACOGENETICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; STATISTICAL MODEL;

EID: 84876881769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062451     Document Type: Article

References (34)

1. Desantis C, Siegel R, Bandi P, Jemal A, (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418.
2. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
5. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
6. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, et al. (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796-1804.
7. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404.
8. Bornstein P, (2002) Cell-matrix interactions: the view from the outside. Methods Cell Biol 69: 7-11.
9. Sage EH, (2001) Regulation of interactions between cells and extracellular matrix: a command performance on several stages. J Clin Invest 107: 781-783.
10. Larsen M, Artym VV, Green JA, Yamada KM, (2006) The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 18: 463-471.
11. Maurer P, Hohenadl C, Hohenester E, Gohring W, Timpl R, et al. (1995) The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J Mol Biol 253: 347-357.
12. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH, (1992) The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and-BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 89: 1281-1285.
13. Arnold SA, Brekken RA, (2009) SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal 3: 255-273.
14. Bradshaw AD, Francki A, Motamed K, Howe C, Sage EH, (1999) Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 10: 1569-1579.
15. Parton RG, Simons K, (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8: 185-194.
16. Guarneri V, Dieci MV, Conte P, (2012) Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. Expert Opin Pharmacother 13: 395-406.
17. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, et al. (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14: 5555-5564.
18. Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, et al. (2010) SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 16: 305-308.
19. Nagai MA, Gerhard R, Fregnani JH, Nonogaki S, Rierger RB, et al. (2011) Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 126: 1-14.
20. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, et al. (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30: 1996-2004.
21. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
22. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
23. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165.
24. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C, (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157.
25. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15: 68-74.
26. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
27. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
28. Schemper M, Smith TL, (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346.
29. Criscitiello C, Azim HA Jr, Schouten PC, Linn SC, Sotiriou C, (2012) Understanding the biology of triple-negative breast cancer. Ann Oncol 23Suppl 6: vi13-18.
30. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, et al. (2008) Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19: 899-909.
31. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324.
32. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, et al. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803.
33. Desai N, Trieu V, Damascelli B, Soon-Shiong P, (2009) SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol 2: 59-64.
34. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29: 4548-4554.